NasdaqGS:NVCRMedical Equipment
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses
NovoCure (NVCR) opened 2026 with Q1 results that follow a year where quarterly revenue ranged from about US$155 million to US$174 million and basic EPS stayed in loss-making territory between US$0.22 and US$0.36 per share. Over that stretch, revenue moved from US$161.3 million in Q4 2024 to US$174.4 million in Q4 2025, while quarterly net losses shifted between roughly US$24.5 million and US$65.9 million. This kept margins under pressure but gave investors a clear read on how top line growth...